Hims Daily (Jun 17, 2025)
Just one more sleep until we "get a taste" 🍏
Today’s Hims Daily is brought to you by … Godel Terminal
People have tried to build a “Bloomberg killer” for years. Godel might actually pull it off. They’re just getting started, but what they’ve already built delivers 90% of Bloomberg’s functionality at 10% of the price. It’s a full trading terminal for $80/month.
We use it daily to track short interest, institutional ownership, analyst ratings, and earnings estimates. If you want access to the data powering Hims House (and a lot more) this is it. Sign up today to lock in lifetime access for $80/mo. First month just $60 if you sign up through Hims House 🔥
Stock Price: $59.20
Today: -$0.58 (-0.97%)
YTD: +$35.02 (+144.83%)
Q2: +$29.65 (+100.34%)
🚨 Starting this week, our HIMS DATA TRACKER will include weekly website traffic across Hims, Hers, Ro, & LifeMD — plus daily app data. Upgrade to paid for access!
What’s Happening
HIMS dropped -1% on macro-driven volatility. In classic HIMS fashion, shares plummeted -6% out of the gate, quickly recovered and surged past $60, then slid back to $56.50 intraday amid Israel-Iran headlines before once again rebounding above $59.
Volume came in at 32M
BUZZ IS OUT OF CONTROL around the June 18 launch. Hers’ teaser over the weekend (“get a taste”) plus yesterday’s gummy-textured “H” “get up close and personal” clip have investors bracing for a personalized gummy reveal. Many see this as a 9-figure opportunity in the booming wellness gummy market, especially if Hims leans into personalized dosing 👀
DTC ad crackdown chatter stirred midday anxiety. Bloomberg reported RFK Jr. and HHS are weighing restrictions on pharma advertising.
Two proposals are reportedly under review: (1) requiring more detailed side effect disclosures in each ad, which could make TV spots longer and cost-prohibitive, and (2) eliminating the tax deduction for DTC ad spending.
Our view is that any crackdown would be a headwind, but the odds are still low, given the current makeup of Congress.
Private market data shows Ro Health’s implied valuation has collapsed. According to Hiive, Ro shares have fallen -83% since July 2023—from $15.33 to $2.54—putting its implied valuation near $1.09B, down from a $6.6B post-money in 2022. Ooooof!
Catalysts
“Get a taste” - June 18 🍏
Lingo CGMs or other wearable partnerships?
More acquisitions still to come?
Move from the Russell 2000 to the Russell 1000 could drive institutional buying. Index reconstitution set for late June.
Pharma tariffs?
Partnership with Eli LillyAny incremental details on the Novo Nordisk roadmap
Upcoming OFA vs. FDA case on semaglutide
Top Tweets
This continuing short interest is beginning to nag at me.